Oriola Oyj Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
October 27, 2022 at 06:30 am
Share
Oriola Oyj reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was EUR 373.9 million compared to EUR 359.3 million a year ago. Net income was EUR 14.6 million compared to EUR 6.8 million a year ago. Basic earnings per share from continuing operations was EUR 0.03 compared to EUR 0.02 a year ago. Diluted earnings per share from continuing operations was EUR 0.03 compared to EUR 0.02 a year ago. Basic earnings per share was EUR 0.08 compared to EUR 0.04 a year ago. Diluted earnings per share was EUR 0.08 compared to EUR 0.04 a year ago.
For the nine months, sales was EUR 1,141.3 million compared to EUR 1,066 million a year ago. Net income was EUR 35.5 million compared to EUR 6 million a year ago. Basic earnings per share from continuing operations was EUR 0.07 compared to EUR 0.03 a year ago. Diluted earnings per share from continuing operations was EUR 0.07 compared to EUR 0.03 a year ago. Basic earnings per share was EUR 0.2 compared to EUR 0.03 a year ago. Diluted earnings per share was EUR 0.2 compared to EUR 0.03 a year ago.
Oriola Oyj, formerly known as Oriola-KD Corporation Oyj, is a Finland-based company active in the pharmaceutical sector. The Company is engaged in the retail and wholesale of pharmaceuticals, acting as a channel between pharmaceutical manufacturers and consumers, primarily in Finland and Sweden. The Company's reporting segments are Consumer, Services, and Healthcare. Through its own pharmacies, the Company provides consumers with not only medicines and pharmaceutical advice but also a selection of healthcare consumer products and customer service. The Company is active through a number of subsidiaries located throughout Europe, including PharmaService OY, Oriola AB, Oriola Oyj, Farenta Oy, Kronans Droghandel Apotek AB and Svensk dos AB.